Pfizer monitors thousands on COVID pill for safety and effectiveness
NCT ID NCT05263908
Summary
This study aimed to learn about the safety and real-world effects of the approved COVID-19 medicine Paxlovid. Over 3,300 participants aged 12 and up who were prescribed Paxlovid were followed for 28 days. Researchers watched for any side effects and checked whether their COVID-19 symptoms got worse, which helps confirm the medicine's safety profile after it was already on the market.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Local County
Tokyo, 1518589, Japan
Conditions
Explore the condition pages connected to this study.